Upjohn’s Vantin
Executive Summary
Broad-spectrum cephalosporin antibiotic gains additional approval June 4 for the treatment of acute bacterial exacerbation of chronic bronchitis. Specifically, Vantin (cefpodoxime) is approved for the treatment of exacerbations caused by Streptococcus pneumonia, non-beta-lactamase-producing Haemophilus influenzae and Moraxella (Branhamella) catarrhalis. The drug was first approved in August 1992 for mild to moderate infections including acute, community-acquired pneumonia caused by S. Pneumonia and non-beta-lactamase-producing H. influenzae ("The Pink Sheet" Aug. 17, 1992, p. 11).